Ceapro Inc V.CZO

RE:Old jargon

[prophetoffactz]

"...based upon our active outreach and discussions, we expect to secure an alternate development and commercialization partner for Macrilen® for the U.S. and Canada.” AEZS news release; July 13, 2023

A new North American licensing deal for AEZS's diagnostic test could now be imminent and is likely a major driver in H.C. Wainwright's US$15 target price for AEZS and for the merger. Gilles is on the Board of Directors of AEZS and is thereby in a very enviable position to understand the terms being discussed. The terms of the previous Novo Nordisk and Strongbridge deals support H.C. Wainwright's valuation. The benefits of AEZS's test appear considerable. The test is already approved for adults and the benefits can thereby be measured under market conditions. It is now up for potential approval for children with the pediatric trial expected to be fully enrolled in December 2023. People need to judge the case for the test. Gilles may have picked up a screaming bargain at the bottom of the biotech bear market. It could provide capital to fuel CZO's growth.


"Macimorelin has no absolute contraindications [1], unlike the ITT, which is contraindicated in elderly populations and in patients with cardiovascular disease or seizure disorders [2,[5], [6], [7]].Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study - ScienceDirect

"...it gives fewer positive test results than the comparator. EMA considered that it is a priority to avoid over-diagnosis of adult growth hormone deficiency and that GHRYVELIN helps confirm positive diagnosis and so avoid unnecessary treatment of patients with a false positive test result." GHRYVELIN (previously Macimorelin Aeterna Zentaris) | European Medicines Agency (europa.eu)

Bing:

Aeterna Zentaris has developed a growth hormone deficiency (GHD) test using macimorelin, which offers several advantages compared to traditional GH-stimulation tests:

1. Simplicity: The macimorelin test is straightforward and easy to administer. It involves oral administration of macimorelin to the child, followed by blood sample collection within 60 minutes. In contrast, other GH-stimulation tests often require more complex procedures.

2. Minimal Side Effects: Macimorelin is well-tolerated with minimal side effects. This makes it a more comfortable experience for patients, especially children.

3. Fewer Blood Draws: Unlike other tests that may involve multiple blood draws, the macimorelin test typically requires only 3 to 4 blood samples. This reduction in blood draws is beneficial for both patients and healthcare providers.

4. Shorter Duration: The entire process, from administration to blood sampling, is completed in a shorter time frame. This efficiency is advantageous for diagnosing GHD promptly.

5. Accurate Diagnosis: By measuring growth hormone levels in blood samples, the macimorelin test allows for the determination of GHD based on a predetermined threshold value. If the peak growth hormone level falls below this threshold, it indicates pituitary-related GHD.

6. Treatment Option: The patent also covers treating the deficiency with synthetic human growth hormone, providing a comprehensive approach to managing GHD.

In summary, Aeterna Zentaris’ macimorelin test offers simplicity, minimal invasiveness, and accurate diagnosis, making it a valuable alternative to traditional GH-stimulation tests123